× ×ª×× × ×ª×¨×פ×
××רש×
| ××× ×× ×× × ×ספ××
|
|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
B02BX
Other systemic hemostatics
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
פ××× - PER OS
|
| צ×רת ××× ××
|
×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Revolade is indicated for the treatment of patients aged 6 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)Revolade is indicated for the treatment of adult patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.Revolade is indicated for the treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.Revolade is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 6 years and older with severe aplastic anemia.
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 23/01/2011
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×××ר ××××× ×-ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×ס××× ×ª×¨××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ××פ×× ×ס×ר×××××× ×××××× ××××××××× ××.
|
30/01/2020 |
××××××××× |
|
Idiopathic thrombocytopenic purpura, ITP |
|
| ×××ר ××××× ×-ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×ס××× ×תר××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ×××פ×××× ××ק×××××, ×××× ××× ××תר RITUXIMAB ××ר×תת ××××, ×××¢× ××××× ××× ×§×××ת ××ר×ת × ×× ××ר×תת ××××.
|
11/01/2018 |
××××××××× |
|
Idiopathic thrombocytopenic purpura, ITP |
|
| ××× ×¢× ××× 18 ×©× ×× ××××× ×- ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×ס××× ×תר××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ××פ×× ×ס×ר×××××× ×××××× ××××××××× ××. ת×××ת ×××פ×× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××××××××× ×× ××××××××× ×××××.
|
11/01/2018 |
××××××××× |
|
Idiopathic thrmobocytopenic purpura, ITP |
|
| ×××× ×-Aplastic anemia ×§×©× (severe) ×ס××× ×צ××××¤× ××ת (צ×××ר××ת ××× ×¢×¦× ×¤××ת ×-30%, ××××× 2 ×ת×× 3 ×ש×ר×ת: × ××ר×פ×××× ×¤××ת ×-500, ר××ק×××צ×××× ×¤××ת ×-60, ×ס××ת פ××ת ×-20,000), ×©× ×©×ר ×¢× ×¨×ת ×ס××ת × ×××× ×-30,000) ×¢× ××£ ××פ×× ××××× ×ס×פרס××× (ש×××× ×©× Cyclosporine ×¢× anti thymocyte globulin (ATG)).
|
21/01/2016 |
××××××××× |
|
Aplastic anemia |
|
| ×××פ×× ×תר××¤× ××× ×ª× ××××× ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×ס××× ×ª×¨××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ×××פ×××× ××ק×××××, ×××× ××× ××תר RITUXIMAB ××ר×תת ××××, ×××¢× ××××× ××× ×§×××ת ××ר×ת × ×× ××ר×תת ××××.
|
23/01/2011 |
××××××××× |
|
Idiopathic thrombocytopenic purpura, ITP |
|
| ×××× ×-Aplastic anemia ×§×©× (severe) ×ס××× ×צ××××¤× ××ת (צ×××ר××ת ××× ×¢×¦× ×¤××ת ×-30%, ××××× 2 ×ת×× 3 ×ש×ר×ת: × ××ר×פ×××× ×¤××ת ×-500, ר××ק×××צ×××× ×¤××ת ×-60, ×ס××ת פ××ת ×-20,000), ×©× ×©×ר ×¢× ×¨×ת ×ס××ת × ×××× ×-30,000).
|
30/01/2020 |
××××××××× |
|
Aplastic anemia |
|
| 1. ×××ר ××××× ×-ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×× ×¢×קשת (Persistent) ×ס××× ×תר××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ××פ×× ×ס×ר×××××× ×× ××××× ××××××××× ×× 2. ××× ×¢× ××× 18 ×©× ×× ××××× ×-ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×× ×¢×קשת (Persistent) ×ס××× ×תר××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ××פ×× ×ס×ר×××××× ×× ××××× ××××××××× ××.
|
03/02/2022 |
××××××××× |
|
Idiopathic thrombocytopenic purpura, ITP |
|
|
| ש×××ש ×ס×
|
×ס×רת ××××× ×ס×
- ×××פ×× ×תר××¤× ××× ×ª× ×××פ×× ×××× ××××:
- 1. ×××ר ××××× ×-ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×ס××× ×ª×¨××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ××פ×× ×ס×ר×××××× ×××××× ××××××××× ××.
- 2. ××× ×¢× ××× 18 ×©× ×× ××××× ×-×××× ITP (immune thrombocytopenic purpura) ×ר×× ×ת ×ס××× ×ª×¨××××צ××××¤× ×× ×§×©× (ספ×רת ×ס××ת × ×××× ×-30,000) ×××ר ××צ×× ×××פ×××× ××ק×××××.
- 3. ×××× ×-Aplastic anemia ×§×©× (severe) ×ס××× ×צ××××¤× ××ת (צ×××ר××ת ××× ×¢×¦× ×¤××ת ×-30%, ××××× 2 ×ת×× 3 ×ש×ר×ת: × ××ר×פ×××× ×¤××ת ×-500, ר××ק×××צ×××× ×¤××ת ×-60, ×ס××ת פ××ת ×-20,000), ×©× ×©×ר ×¢× ×¨×ת ×ס××ת × ×××× ×-30,000).
|
|
| ×ת××ת ××× ××
|
Posology and method of administration
|
| ×ת××××ת × ××
|
Contraindications
|
| ת×פע×ת ×××××
|
Undesirable effects
|
| ת××××ת ××× ×ª×¨×פת××ת
|
Interaction with other medicinal products and other forms of interaction
|
| ש×××ש ×××ר××× ××× ×§×
|
Pregnancy and Lactation
|
| פר×ק×××× ××ק×
|
Pharmacodynamic Properties
|
| פר×ק×ק×× ××ק×
|
Pharmacokinetic Properties
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
ת×ר×× ×¢××××: 26/11/2025
LEK
ר×××××× - Revolade
true
השינוי האחרון נעשה בֹ־26 בנובמבר 2025 ב־09:14
